IBB250110C150000
- 0.38
- 0.000.00%
iShares Biotechnology ETF Newsroom
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Merck Downgraded by Truist to Hold Over Growth Concerns
Sector Update: Health Care Stocks Rise Premarket Wednesday
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of FOMC Meeting Minutes
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Amgen Analyst Ratings
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Looking Into Gilead Sciences's Recent Short Interest
Vertex Grapples With Bearish Chart As Death Cross Emerges
Alnylam Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today